Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
TLSIthis companyTriSalus Life Sciences, Inc.	$3.41	-3.79×	-7.81×	5.86×	-8.43×	-3311.9%	84.6%	-59.7%	-86.9%	115.8%	-112.3%	-7.2%	-1.02×	-0.42×	-4.86×	2.8×	0.0%	2	-4.71	1	D+
ARMPArmata Pharmaceuticals, Inc.	$3.36	-1.31×	-1.04×	46.41×	-3.26×	-475.8%	68.8%	-636.7%	-3544.0%	79.5%	-43.1%	-11.6%	-1.32×	-1.79×	-1.88×	1.19×	0.0%	2	-17.44	2	C
AVRAnteris Technologies Global Corp.	$5.96	-1.96×	-1,980.52×	96.28×	-1.88×	-109.8%	-16.6%	-4908.2%	-4921.3%	101230.1%	-4256.3%	-43.3%	-24.54×	0.11×	-1,286.22×	0.73×	0.0%	3	13.88	2	C
CATXPerspective Therapeutics, Inc.	$0.82	-1.96×	0.98×	0×	-1.74×	-87.1%	0.0%	0.0%	0.0%	-49.8%	-47.2%	-46.9%	0.02×	0.27×	-302.03×	5.17×	0.0%	3	-0.5	3	B-
LNSRLENSAR Inc	$5.50	-4.05×	-5.34×	2.38×	-4.33×	-927.5%	46.4%	-42.1%	-58.7%	131.7%	-77.8%	-10.7%	-0.11×	0.34×	0×	1.15×	0.0%	5	0.85	4	A-
MXCTMaxCyte, Inc.	$1.28	-3.69×	0.96×	4.99×	-4.12×	-294.2%	81.2%	-137.1%	-135.1%	-26.0%	-23.9%	-21.9%	0.1×	0.05×	0×	8.3×	0.0%	2	1.63	2	C+
Peer median	—	-1.96×	-1.04×	4.99×	-3.26×	-294.2%	46.4%	-137.1%	-135.1%	79.5%	-47.2%	-21.9%	-0.11×	0.11×	-1.88×	1.19×	0.0%	3	0.85	2	—